Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis.
Viruses
; 16(5)2024 05 17.
Article
de En
| MEDLINE
| ID: mdl-38793680
ABSTRACT
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that pre-existing spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Fibrose
/
Lymphocytes T CD8/
/
Antigène CD274
/
Inhibiteurs de points de contrôle immunitaires
/
Immunothérapie
/
Chorioméningite lymphocytaire
/
Virus de la chorioméningite lymphocytaire
Limites:
Animals
Langue:
En
Journal:
Viruses
Année:
2024
Type de document:
Article
Pays d'affiliation:
Espagne
Pays de publication:
Suisse